Publications. methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision Read More NICE STA, rare diseases Matthijs Versteegh 11/16/20 NICE STA, rare diseases Matthijs Versteegh 11/16/20 Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment Read More
methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 methods, rare diseases, Pharmacoeconomics Matthijs Versteegh 2/19/21 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision Read More
NICE STA, rare diseases Matthijs Versteegh 11/16/20 NICE STA, rare diseases Matthijs Versteegh 11/16/20 Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment Read More
